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We herein report on 3 nonsense and 1 deletion mutations in TSC1 or TSC2 genes in 
10 Japanese individuals with various phenotypes of tuberous sclerosis complex (TSC). 
Even having identical mutations, some patients suffered from intractable epilepsy and 
showed severe intellectual and behavioral disabilities, while others were intellectually 
normal and epilepsy was absent or easily controlled.  Review of the data of these and 
other 196 cases in the literature revealed that certain missense mutations are character-
istic in yielding mild phenotype, particularly at the GTPase-activating protein domain of 
TSC2 gene.  Non-truncating mutations in this functionally important domain may tend 
to cause clinical symptoms, while those in the other regions may remain subclinical and 
interpreted as polymorphism.  On the other hand, many truncating and missense muta-
tions of TSC genes could cause either mild or severe phenotypes.  Somatic mosaicism, ei-
ther in the initial or second-hit mutations, cannot explain the whole feature of this clini-
cal variability.  Mutation database with sufficient information of clinical manifestations 
and family history is necessary to draw reliable conclusion for genetic counseling, as well 
as to evaluate any modifying factors on the clinical severity other than the TSC gene mu-
tations.
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Tuberous sclerosis complex (TSC) is a disorder 
with autosomal dominant inheritance, character-
ized by development of hamartomatous lesions in 
various organs and a wide range of neurological 
abnormalities.  Two genes causing TSC have been 
identified: TSC1 is located at chromosome 9q34 
and encodes hamartin, and TSC2 is at chromo-
some 16p13.3 and encodes tuberin.  These proteins 
interact and form a cytoplasmic heterodimer com-
plex that inhibits the phosphorylation of mamma-
lian target of rapamycin (mTOR) pathway (Swiech 
et al., 2008), and play a cardinal role in the regula-
tion of differentiation, growth, and proliferation of 
various cell types.
 The disruption of mTOR pathway could 
explain the extracerebral complications; i.e., an 
* http://chromium.liacs.nl/LOVD2/TSC/home.php?select_
db=TSC1 or db=TSC2
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inherited mutation is carried in one allele, and the 
second mutation in the other allele of TSC genes 
have been identified in the hamartomatous lesions 
of TSC patients.  However, this second hit has not 
been identified in the dysplastic cerebral tissues 
of TSC patients, including cortical tubers (Niida 
et al., 2001; Ramesh et al., 2003).  In addition, 
studies on the genotype-phenotype correlations 
in TSC mutants have revealed that mutations in 
TSC2 gene tend to cause more severe neurological 
outcome than TSC1 gene mutations (Dabora et al., 
2001; Sancak et al., 2005; Au et al., 2007), result-
ing in lower intelligence quotient and higher prev-
alence of autistic traits and infantile spasms (Lewis 
et al., 2004).  Variation of severity can be seen 
even between monozygotic twins with identical 
TSC gene mutations (Gomez et al., 1982; Martin 
et al., 2003; Humphrey et al., 2004).  These facts 
have made the pathogenesis of cerebral lesions dif-
ficult to understand and the prognosis of individual 
TSC patients hard to predict.
 In order to have a better insight into the clini-
cal variability of TSC patients, particularly re-
garding neurological complications, we reviewed 
our Japanese series of TSC gene mutations and 
compared the clinical features of patients with 
identical mutations.  In addition, we reviewed 
the around 400 TSC1 and 1,000 TSC2 mutations 
that have been reported to date*, and identified 
5 TSC1 mutations and 33 TSC2 mutations that 
have been found in different members of a single 
family or in individuals from different families, 
for whom clinical data were also provided in the 
literature (Smalley et al., 1994; Vrtel et al., 1996; 
Wilson et al., 1996; Jobert et al., 1997; Mahesh-
war et al., 1997; Au et al., 1998; Beauchamp et 
al., 1998; Kwiatkowska et al., 1998; Verhoef et al, 
1998, 1999; Niida et al., 1999; Zhang et al., 1999; 
Yamashita et al., 2000; Dabora et al., 2001; Yama-
moto et al., 2002; Martin et al., 2003; Feng et al., 
2004; Humphrey et al., 2004; Mayer et al., 2004; 
Ali et al., 2005; Rok et al., 2005; Choi et al., 2006; 
Hung et al., 2006; Jansen et al., 2006; Lyczkowski 
et al., 2007).  We found that certain mutations 
were identified in patients with various severities, 
or otherwise were common in mildly affected 
patients.  Analysis on the mutation types, either 
truncating or missense, also revealed that missense 
mutations were clustered in the GTPase-activating 
protein (GAP) domain of TSC2 gene.  Significance 
of these findings is discussed.
 
 
Subjects and Methods
 
In the series of 140 Japanese patients, clinically 
suspected with either definite, probable or pos-
sible TSC (Roach et al., 1998), mutation analysis 
of TSC1 and TSC2 genes in blood samples was 
performed by means of polymerase chain reaction-
single strand conformation polymorphism analysis 
as described in previous reports (Zhang et al., 
1999; Yamamoto et al., 2002).  We found TSC1 
mutation in 20 patients, and TSC2 mutation in 
49 patients.  Out of the 20 TSC1 mutations, there 
were 9 missense mutations, 4 nonsense mutations, 
4 insertions, 3 deletions.  The 49 TSC2 mutations 
included 25 missense mutations, 5 nonsense mu-
tations, 3 insertions, 9 deletions, and 7 mutations 
in the intron sequence that were considered to 
result in splicing errors.  Among these, there were 
4 sets of patients with the same type of the muta-
tions.  These identical mutations were present in 
3 patients having the same TSC1 mutations, and 
7 patients in 3 sets of TSC2 mutations.  Clinical 
data of these 10 patients were collected in terms of 
cutaneous, cardiac, renal, and liver involvement, as 
well as the presence and nature of epilepsy, intel-
lectual assessment, autistic traits, and findings on 
neuroimaging (computed tomography (CT) in 9, 
and magnetic resonance (MR) imaging in 6 pa-
tients).  Some data of patients 1, 2, 5, 6 and 7 have 
been published previously (Zhang et al., 1999; 
Feng et al., 2004).
 
Results
 
TSC1 c.1746C>T (p.R509X) mutation (Table 1)
 
 Patient 1:  This patient, a 41-year-old woman, 
suffered from infantile spasms when she was 2 
months old.  Adrenocorticotropin was effective 
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Table 1.  Clinical features of patients with TSC1 c.1746C>T (p.R509X) mutation
          Symptom Patient 1 Patient 2 Patient 3
Age examined (yr) 41 27 62
Sex Female Male Male
Heredity Sporadic Familial Sporadic
Type of epileptic seizures
 Infantile spasms g com- 
 plex partial seizures 
(No seizures) Complex partial seizures
Onset of seizure 2 mo Not applicable School age
Control of seizure Good Not applicable Good
Mental retardation Severe (DQ < 10)   – –
Autism – – –
Impaired social interaction – – –
Stereotypical behavior – – –
Other autistic behaviors – – –
Hypomelanotic macule – + +
Facial angiofibroma – – +
Shagreen patch  – Not described +
Renal angiomyolipoma + + +
Periventricular calcification
    on brain CT 
+ + +
Cortical tuber + + +
Other symptoms Triplegia, mastoadenoma
  Liver cyst, adrenal nodule  
   (1.5 mm), ungual fibroma
 –, absent; +, present; DQ, developmental quotient; mo, months; yr, years.
Fig. 1.  Neuroimaging of patients with TSC1 p.R509X mutation.  A to D: Patient 1.  E and F: Patient 2.  A and B: 
computed tomography (CT).  C to F: magnetic resonance (MR) imaging [C: T1 weighted image, D to F: Fluid-attenu-
ation recovery images].
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Table 2.  Clinical features of patients with TSC2 c. 3355C>T (p.Q1119X) mutation
          Symptom Patient 4 Patient 5
Age examined (yr) 8 23
Heredity Sporadic Sporadic
Type of epileptic seizures Infantile spasms Right hemiconvulsion
Onset of seizure 6 mo 13 mo (with fever)
Control of seizure Good Only once
Mental retardation Severe (DQ 17) Normal intelligence
Autism + –
Impaired social interaction + (disobedience) –
Stereotypical behavior ++ –
Other autistic behaviors Panic, self injury –
Hypomelanotic macule + –
Facial angiofibroma + –
Renal angiomyolipoma – 2 (diameter 1 cm, 19 yr)
Periventricular calcification 
     on brain CT 
8 4
Cortical tuber + Not available
Other symptoms Cardiac rhabdomyoma,  Renal cystic dysplasia with cancer-like lesions
 Wolff-Parkinson-White syndrome (3 mo), angiomyolipoma of liver (15 yr)
–, absent; +, present; ++, marked; DQ, developmental quotient; mo, months; yr, years.  
Fig. 2.  Neuroimaging of Patient 4 
with TSC2 p.Q1119X mutation. 
 A: CT image.  
 B: Fluid-attenuation recovery 
MR image.
in treatment of her epilepsy, and subsequent complex partial seizures 
have been controlled well.  Paraparesis and left hemiparesis have been 
noted, and a large cortical tuber with calcification at the medial part 
of right frontal lobe has been revealed on neuroimaging (Figs. 1A to D).
 Patient 2:  The patient is a 27-year-old man, who has hypomel-
anotic macules, but has not shown intellectual disability or epileptic 
seizures. A small number of subependymal nodules and cortical tu-
bers are noted (Figs. 1E and 1F), but less evident compared to Patient 1. 
Clinical data on other family members were not available.  
 Patient 3:  This 62-year-old man is intellectually normal.  He 
suffered from epilepsy in his school years, which was well controlled 
by antiepileptics thereafter. 
 
TSC2 c.3355C>T (p.Q1119X) mutation (Table 2)
 
 Patient 4: This 8-year-old girl suffered from infantile spasms 
at age 6 months.  Residual seizures are currently controlled by potas-
sium bromide, but she shows severe intellectual disability and autistic 
behavior including panic and self injury.  Numerous cortical tubers 
and subependymal nodules are noted on neuroimaging (Fig. 2).
 Patient 5: A large renal tumor, histologically identified as cystic 
dysplasia with renal cancer, was resected when this girl was 3 months 
old.  She suffered from febrile hemiconvulsion at age 13 months, 
but seizure never recurred thereafter, and electroencephalography 
remained normal.  Intracranial calcifications and hepatic angiomyo-
lipoma were revealed at the age of 15 years.  She shows normal intel-
ligence and has graduated from college. 
A
B
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Table 3.  Clinical features of patients with TSC2 c. 4393 C>T (p. R1459X) mutation
          Symptom Patient 6 Patient 7
Age of examined patient (yr) 18 19
Sex Male Female
Heredity Familial Sporadic
Type of epileptic seizures Complex partial seizures Complex partial seizures
Onset of seizure 3 yr and 2 mo 1 yr
Focus in electroencephalography Right fronto-parietal, left frontal Right frontal
Control of seizure
 Fair (  twice a year since 12 yr) Poor  excision of right frontal 
  lobe (17 yr)  good
Mental retardation IQ 33 IQ 41
Autism + +
Impaired social interaction + + (likes to play alone)
Stereotypical behavior Preoccupation with special events Compulsive
Other autistic behaviors Difficult to adapt to changes Anxious, easily excited
Hypomelanotic macule Not available +
Facial angiofibroma Not available +
Renal angiomyolipoma + many  embolization
Periventricular calcification 
     on brain CT 
+ several, 1 in right frontal
Brain MRI
 Cortical tubers,  Cortical tubers
 bilateral subependymal nodules 
+, present; IQ: intelligence quotient; mo, months; yr, years.
Fig. 3.  Radiological findings of patients 
with TSC2 p.R1459X mutation.  
 A: brain CT of Patient 6.  
 B: brain MR imaging of Patient 7.
 C:  abdominal CT image  of Patient 7.
Arrows in C indicate the angiomyolipoma 
in bilateral kidneys.
 
TSC2 c.4393C>T (p.R1459X) mutation (Table 3)
 
 Patient 6:  This patient suffered from epilepsy with complex 
partial seizures since age 3.  He is now 18 years old, and seizures still 
appear twice per year despite treatment.  Moderate intellectual dis-
ability and autistic traits have been evident.  Multiple subependymal 
nodules (Fig. 3A) and cortical tubers are noted.  Data on other family 
members with TSC were not available.
 Patient 7:  This girl suffered from intractable, complex partial 
seizures since 1 year of age, which disappeared after resection of the 
right frontal lobe at age 17.  She has moderate intellectual disability, 
likes to play on her own, and shows anxious and compulsive behav-
iors.  Numerous cortical tubers (Fig. 3B) are noted on MR imaging. 
Renal angiomyolipoma (Fig. 3C) were treated with arterial emboliza-
tion at age 17 years.
A
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TSC2 c.5238–5255del (p.del 1746HIKRLR) 
mutation (Table 4)
 
 Patient 8:  This patient, a severely retarded 
but not autistic boy, suffered from infantile spasms 
at age 4 months, which evolved into localization-
related epilepsy and remained intractable.
 Patient 9:  This patient also developed infan-
tile spasms and complex partial seizures at age 5 
months.  The seizures have been intractable, and 
she shows severe intellectual disability and autism.
 Patient 10:  This boy developed infantile 
spasms when he was 5 months old.  He gained the 
ability to utter meaningful words since 2 years of 
age.  He was hyperactive and had difficulties in so-
cial relationships during early childhood. However, 
his social skills improved since he was 5.  When 
he was 13, he was no longer autistic, but showed 
occasional, compulsive behaviors.
Table 4.  Clinical features of patients with TSC2 c.5238–5255del (p. del 1746 HIKRLR) mutation
          Symptom Patient 8 Patient 9 Patient 10
Age of examined patient (yr) 3 6 13
Sex Male Female Male
Heredity Sporadic Sporadic Sporadic
Type of epileptic seizures Infantile spasms CPS, infantile spasms Infantile spasms
Onset of seizure 4 mo 6 mo 5 mo
Focus in   Right front-parietal, 
     electroencephalography  right frontal, right central, 
  left parieto-temporal?
Control of seizure Good (since 2 yr) Fair (5–10 times/day) Once in 3 mo
Mental retardation Moderate–severe Severe (DQ 35 at 2 yr) Moderate (IQ 45–50)
Autism – + –
Impaired social interaction – + (lack of social  + (until 2–3 yr) g
  reciprocity, failure  –  (since 5 yr)
  to use eye-to-eye gaze)
Communication disturbance – + (nonverbal) –
Stereotypical behavior – Not available + (mild)
Other autistic behaviors –
Hypomelanotic macule + + +
Facial angiofibroma + – –
Renal angiomyolipoma – – –
Other renal lesions   One renal cyst in the right 
   kidney, bilateral lipoma 
Periventricular calcification
     on brain CT 
+ + +
Brain MRI Not available + Subependymal nodules, 
   multiple subcortical  
   hypomyelination
Other symptoms Cardiac rhabdomyoma, 
 fibroma on the occiput
–, absent; +, present; CPS, complex partial seizures; DQ, developmental quotient; IQ, intelligence quotient; mo, months; yr, years. 
 
TSC patients with identical mutations in 
the literature (Table 5)
 
By adding the 10 patients in this study, we could 
identify 5 TSC1 mutations in 17 patients, and 33 
TSC2 mutations found in 179 patients (Table 5), 
which were found in 2 or more individuals.   Most 
of these groups with identical mutations, either 
truncating or non-truncating, included both indi-
viduals with normal and disabled intelligence.  In 
contrast, individuals with L61R mutation in TSC1, 
and K12X, E1542K, 1554Q, G1556S, and 1628X 
mutations in TSC2, did not show intellectual dis-
abilities, even having multiple cortical tubers. 
R905Q mutation of TSC2 gene also showed re-
sultant tendency of milder cognitive impairment. 
Out of the 14 missense mutations in TSC2, 6 were 
concentrated at exons 34 to 38, which corresponds 
to the GAP homology domain (Maheshwar et al., 
1997). 
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Lyczkowski (2007)
 A-I-1 (father) F TSC1 exon 4 403T>G L61R 51 m MM IQ 100  Controlled 14 +  + + +   +  – 
 A-II-1 (sib) F TSC1 exon 4 403T>G L61R 21 f MM IQ 101  Occasional 12 +  + + + +  –  – 
 A-II-2 (sib) F TSC1 exon 4 403T>G L61R 17 f MM IQ 72  Intractable 18 +  + + +      
Kwiatkowska (1998)
 Mother F TSC1 exon 15 2105 del AAAG  27 f FS     +   + + +     
 Sib 1 F TSC1 exon 15 2105 del AAAG  7  FS Severe MR  +  +          
 Sib 2 F TSC1 exon 15 2105 del AAAG  3  FS MR (–)  –    +        
Hung (2006) 
 61 F TSC1 exon 15 1525C>T R509X 3.5 m NM LD  + +   + + – – –   – 
Zhang (1999), the present study
   3; Patient 1 S TSC1 exon 15 1746 C>T R509X 41 f NM Severe MR – IS, partial Sz + ++  – –  – +    
 26; Patient 2 F TSC1 exon 15 1746 C>T R509X 27 m NM MR (–) – – + +  + –   +    
The present study
 Patient 3 S TSC1 exon 15 1746 C>T R509X 62 m NM MR (–) – + +   + + + + +    Liver cyst 
                         s/o, adre- 
                        nal nodule
Niida (1999)
 Family 26 F TSC1 exon 17 2295 C>T R692X   NM MR  + Brain   + + Var Var –   – (retinal HM)
             image (+)
 Family 38 F TSC1 exon 17 2295 C>T R692X   NM MR (–)/LD  + Brain   – – + – +   NA 
             image (+)
Lyczkowski (2007)
 C-I-1 F TSC1 exon 20 2790insG  88 m FS NA  NA NA NA NA  + + +  NA +
 C-II-2 F TSC1 exon 20 2790insG  55 f FS NA  NA NA NA NA + + +   NA NA NA 
 C-II-3 F TSC1 exon 20 2790insG  52 m FS NA  NA NA NA NA NA NA NA NA NA NA NA NA 
 C-III-1 F TSC1 exon 20 2790insG  31 m FS IQ 87  Intractable + + +  + +  – – – – 
 C-III-2 F TSC1 exon 20 2790insG  30 m FS NA  Controlled + + + +    – – –  Retinal HM
 C-III-3 F TSC1 exon 20 2790insG  28 m FS Impaired  Intractable NA NA NA + + + + – – – – 
 C-III-4 F TSC1 exon 20 2790insG  27 m FS IQ 79  Controlled  9 +  +    +   – 
 C-III-5 F TSC1 exon 20 2790insG  23 f FS IQ 73  Intractable 45 +  +    – – –  Retinal HM
Vrtel (1996)
 Father  F TSC2 exon 1 52A>T K12X  30 m IF?       –        Gingival 
      (1–49 del?)                  fibroma
 Son F TSC2 exon 1 52A>T K12X  1.5 m IF? MR (–)      +       +
      (1–49 del?)
Verhoef (1999)
 Family 4 sib 1 F TSC2 intron 1 156+1G>A 31X  m FS MR (–)  IS + +  + +       
 Family 4 sib 2 F    TSC2 intron 1 156+1G>A 31X  m FS Mild MR  + + +  + +      + Gingival
                         fibroma
Table 5.  TSC patients with identical mutations in the literature [i]
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Wilson (1996)
 TSC-028-1 F TSC2 exon 12 1365G>C M449I   MM MR(–) Beh/ +  CT (+)  + – + –     Eye (+)
           LD (–)
 TSC-028-2 F TSC2 exon 12 1365G>C M449I   MM MR  +    + + – –     Eye (–)
 TSC-028-3 F TSC2 exon 12 1365G>C M449I   MM     CT (–)   + +  Renal 
                    ab (+)
 TSC-028-4 F TSC2 exon 12 1365G>C M449I   MM MR  +  CT (+)  + – – –     Eye (–)
Beauchamp (1998)
 F17-01 F TSC2 exon 12 1348G>T E450X 3  NM Mild MR  + Brain find-   + – – – NA   –
             ings (+)
 F16-01 F TSC2 exon 12 1348G>T E450X 3  NM MR(–)  + Brain find-   + – – – NA   –
             ings (+)
Niida (1999)
 326 S TSC2 exon 12 1348G>T E450X   NM MR  + Brain   + – – – –   + Retinal HM
             image (+)
Jobert (1997)
 B17 II-1 (father) F TSC2 exon 14 1462del33  482–492 del  m IF MR (–)  + MRI (+) CT (+)  + + + + Renal    Eye (–)
     mRNA               ab (+) 
 B17 III-2 (son) F TSC2 exon 14 1462del33  482–492 del  m IF MR   +    + + + + Renal 
     mRNA               ab (–) 
 B95 I-1 (mother) F TSC2 exon 14 1462del33  482–492 del  f IF MR (–)  + MRI (+) CT (+)  – + + – Renal   Eye (+)
     mRNA               ab (+) 
 B95 II-1 (son) F TSC2 exon 14 1462del33  482–492 del  m IF MR  + MRI (+) CT (+)  + + + + Renal   Eye (+)
     mRNA               ab (+) 
Au (1998)
 TS94-96  TSC2 exon 14 1513C>T R505X   NM MR Beh/ + + +  + + + +    + Eye (–)
           LD (+)
Wilson (1996)
 TSC-037-1 F TSC2 exon 14 1531C>T R505X   NM MR (–)  +  CT (+)   + +      
 TSC-037-2 F TSC2 exon 14 1531C>T R505X   NM MR (–) Beh/ +    + + + –     
           LD (+)
Hung (2006)
 20 S TSC2 exon 14 1513C>T R505X  m NM MR (–)  + +   + + – – (+)?    
 57 S TSC2 exon 14 1513C>T R505X  f NM MR  + +   + + – + –    
Niida (1999)
 53 F TSC2 exon 16 1832G>A R611Q   MM MR (–)  + Brain    + + – – NA   +
             image (+)
Au (1998)
 TS94-31  TSC2 exon 16 1832G>A R611Q   MM MR Beh/ + + +  + + – – –  – + Eye(+)
           LD (+)
 TS93-29  TSC2 exon 16 1832G>A R611Q   MM MR  + + +  + – – – –  – – 
Table 5.  TSC patients with identical mutations in the literature [ii]
65
V
ariations in identical T
SC
 m
utations
Pro
teinPatient
Reference
He
red
ity
DN
A c
han
ge Ag
e
Oth
ers
CR
Ren
al
cys
t
RC
C
Shg
P
AFSE
GA AM
L
PU
F
HP
M
SE
N
Tub
er
Sei
zur
e
Au
tism
Int
elli
gen
ce
Mu
tati
on 
typ
eSex
Table 5, continued to the next page.  Footnotes, refer to Table 5 [vii], end of this table.
(ye
ar)
Wilson (1996)
 TSC-382 F TSC2 exon 16 1849C>T R611W   MM MR  +  CT (+)  + + + + Renal    Eye (–)
                    ab (+)
Ali (2004)
 TS-07 S TSC2 exon 16 1832G>A R611Q 9  MM MR (–) NA + NA NA NA + + – + NA   NA 
 TS-23 S TSC2 exon 16 1831C>T R611W 2  MM MR + + + + – + – – + NA   NA 
Hung (2006)
 29 S TSC2 exon 16 1832G>A R611Q  f MM MR  + +   + – – + –    
Zhang (1999)
 22 F TSC2 exon 16 1850G>A R611Q 6 f MM MR(–)  +  +  + –       
Beauchamp (1998)
 F03-01 F TSC2 exon 16 1832G>A R611Q 5  MM MR(–)  + Brain find-   + – – – –   – 
             ings (+)
Hung (2006)
 82 S TSC2 exon 17 1939G>A D647N  m MM MR (–)  + –   – – – – –    
Zhang (1999)
 32 S TSC2 exon 17 1957G>A D647N 2 m MM NA  +  +  + NA       
Zhang (1999)
 21 F TSC2 exon 20 2324T>G V769E 44 f MM MR (++)  NA  NA  + +       
   2 S TSC2 exon 20 2324T>G V769E 32 m MM MR (++)  +  +  + +       
Verhoef (1999)
 Family 3 sib 1 F TSC2 intron 20 2374-2 A>C   f SP Moderate MR +  (+)?  + +  +    + 
 Family 3 sib 2 F TSC2 intron 20 2374-2 A>C   f SP Severe MR  +  (+)?   + +  +   + 
Beauchamp (1998)
 F08–01 F TSC2 exon 23 2714G>A R905Q 10  MM MR (–)  + Normal Normal  + + + + NA   NA
Jansen (2006)
 Family A (n = 25) F TSC2 exon 23 2714G>A R905Q 6  MM MR (–) 12,   15/25 5/15  1 1 23/    1  1 0/ 0/
       –   LD 10,    WML   25       12 16
       61   mild CI 3
 Family B (n = 3) F TSC2 exon 23 2714G>A R905Q NA  MM MR (–) 1,  2 2   3 1   NA   NA 
          mild CI 2
 Family C (n = 9) F TSC2 exon 23 2714G>A R905Q NA  MM MR (–) 6,   6 1/1    8 1 2 2    1/1 
          impaired 1,   examined          exam-
          severe CI 1             ined
 Family D (n = 1) F TSC2 exon 23 2714G>A R905Q NA  MM MR (–)  + –   +   + NA  NA NA 
 Family E (n = 1) F TSC2 exon 23 2714G>A R905Q NA  MM MR (–)  + abn   +    –  – – 
 P1 S TSC2 exon 23 2713C>T R905W NA  MM NA  – + +  + +   NA  NA NA 
 P2 S TSC2 exon 23 2713C>T R905W NA  MM Mild CI  Remitted + +  + +  + –  – – Retinal HM
 P3 S TSC2 exon 23 2713C>T R905W NA  MM Moderate CI  Active + +  +    –  – + 
 P4 S TSC2 exon 23 2713C>T R905W NA  MM Severe CI  Active LGS + +  +    –  – – 
 P5 S TSC2 exon 23 2713C>T R905W NA  MM MR(–)  – +  + + +     + – 
 P6 S TSC2 exon 23 2713C>T R905W NA  MM Severe CI  + + +  + +   –   NA 
 P7 S TSC2 exon 23 2713C>T R905W NA  MM Severe CI  + NA NA NA     NA  NA NA 
 P8 S TSC2 exon 23 2713C>T R905W NA  MM Mild CI  Remitted IS + +  + + + + +  – NA 
Table 5.  TSC patients with identical mutations in the literature [iii]
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Au (1998)
 TS95-12  TSC2 exon 23 2713C>T R905W   MM MR  + + +  + – – – –  – – 
Yamamoto (2002)
 8 S TSC2 exon 23  2713C>T R905W 21 f MM IQ 40  + + +  + +    Renal 
                     tumor
Yamashita (2000)
 1  TSC2 exon 23 2713C>T R905T   MM Moderate MR IS    + +       
Yamamoto (2002)
 7 S TSC2 exon 23  2713C>G R905G 3 m MM Neurological   IS + +  +       + 
          symptoms (+)
Hung (2006)
 64 S TSC2 exon 26 2974C>T Q992X  m NM MR (–)  + +   + – – – –    
Beauchamp (1998)
 S17-01 S TSC2 exon 26 2974C>T Q992X 5  NM Moderate MR + Brain find-   + + – – –   NA Retinal 
             ings (+)           findings (+)
The present study
 Patient 4 S TSC2 exon 28 3355C>T Q1119X 8 f NM DQ 17 + IS + +  + +   –   + 
Feng (2004), the present study
 4, Patient 5 S TSC2 exon 28 3355C>T Q1119X 23 f NM MR (–) – Febrile Sz NA +  – –   + Renal   Liver AML
                     tumor
Humphrey (2004)
 Twin A F TSC2 exon 29 3043delC truncation  3 m FS DQ 45 + Partial Sz Extensive
      1210?
 Twin B F TSC2 exon 29 3043delC truncation 3 m FS DQ 71 Partial IS +
      1210?
Wilson (1996)
 TSC-001-1 father F TSC2 exon 29 3616C>T R1199W  m MM  Beh/ + MRI (–) CT (–)  + – – –     
           LD (+)
 TSC-001-2 sib F TSC2 exon 29 3616C>T R1199W   MM    MRI (+) CT (–)  + + –      
 TSC-001-3 sib F TSC2 exon 29 3616C>T R1199W   MM MR   + MRI (–) CT (–)  + – – +     Eye (–)
Lyczkowski (2007)
 D-I-1 F TSC2 exon 33 4422–4423del  NA m FS NA  Controlled NA NA NA +    NA NA NA NA 
 D-II-2 F TSC2 exon 33 4422–4423del  NA m FS NA  Controlled NA NA NA +    NA NA NA NA 
 D-II-3 F TSC2 exon 33 4422–4423del  NA f FS NA  Controlled NA NA NA +    NA NA NA NA 
 D-III-1 F TSC2 exon 33 4422–4423del  9 f FS NA  IS 39 + + + +   –   + 
 D-III-2 F TSC2 exon 33 4422–4423del  6 f FS IQ 85  IS + + + + +   –   + 
 D-III-3 F TSC2 exon 33 4422–4423del  3 m FS IQ 101  IS 49 + + +    +    
Table 5.  TSC patients with identical mutations in the literature [iv]
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Niida (1999)
 171 S TSC2 exon 33 4421–4422del R1474fs   FS MR  + Brain    + + + + NA  NA NA 
      1521X       image (+)
 311 S TSC2 exon 33 4422–4423del R1474fs   FS MR (–)  + Brain    + – – – NA  NA NA 
      1521X       image (+)
Niida (1999)
 187 F TSC2 exon 33 4375C>T R1459X   NM MR  + Brain    + + – + –  – + Retinal 
             image (+)           HM
Zhang (1999), the present study
 6, Patient 6 F TSC2 exon 33 4393C>T R1459X 18 m NM IQ 33 + Controlled + +  NA NA   +    
 8, Patient 7 S TSC2 exon 33 4393C>T R1459X 19 f NM IQ 41 + Surgery + +  + +   +    
Smalley (1994)
 n = 17 F TSC2 exon 34 4508A>C Q1503P   MM IQ<70  4/17   (–) in 10 –          Psychiatric 
                        disorder 
                        13/17
Wilson (1996)
 TSC-422-1 F TSC2 exon 34 4519–4547 dup L1510fs   FS MR  +  CT (+)  + + – + Renal   Eye (–)
      1541X              ab (+)
 TSC-422-2 F TSC2 exon 34 4519–4547 dup L1510fs   FS NA  –    + + + + Renal    Eye (–)
      1541X              ab (+)
Jansen (2006)
 Family F II-3 F TSC2 exon 35 4642G>A E1542K   MM MR (–)  – +   + + +  +    
 Family F III-3 F TSC2 exon 35 4642G>A E1542K   MM MR (–)  – +   + + –      
 Family F III-5 F TSC2 exon 35 4642G>A E1542K   MM MR (–)  – +   + + –      
 Family F IV-3 F TSC2 exon 35 4642G>A E1542K   MM MR (–)  + +   + + –      
 Family F IV-4 F TSC2 exon 35 4642G>A E1542K   MM MR (–)  – +   + + –      
 Family F IV-7 F TSC2 exon 35 4642G>A E1542K   MM MR (–)  – +  + + + –      
 Family F IV-8 F TSC2 exon 35 4642G>A E1542K   MM MR (–)  – +   + + –      
 Family F IV-9 F TSC2 exon 35 4642G>A E1542K   MM MR (–)  – +   + + –      
 Family F V-3 F TSC2 exon 35 4642G>A E1542K   MM MR (–)  + +   – – –      
 Family F V-4 F TSC2 exon 35 4642G>A E1542K   MM MR (–)  – +   – – –      
Lyczkowski (2007)
 E-I-1 F TSC2 exon 35 4662G>A 1554Q 62 m SP IQ 106  NA 7 + +     NA NA NA NA 
 E-II-1 F TSC2 exon 35 4662G>A 1554Q 39 f SP IQ 115  NA 12 +      NA NA NA NA 
 E-II-2 F TSC2 exon 35 4662G>A 1554Q 38 m SP NA  None  + +  +   +  +  Hepatic cyst
 E-II-4 F TSC2 exon 35 4662G>A 1554Q 34 f SP IQ 105  NA 8 +      NA NA NA NA 
 E-III-1 F TSC2 exon 35 4662G>A 1554Q 5 m SP IQ 102  Controlled 14 + + + +  + – – – + Retinal 
                        pigment
 E-III-2 F TSC2 exon 35 4662G>A 1554Q 3 m SP IQ 121  None 18 + + + +   – – – – 
Table 5.  TSC patients with identical mutations in the literature [v]
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Mayer (2007)
 IV-3 F TSC2 exon 36 4684G>A G1556S 3 m MM MR (–)  –  –  +       + 
 IV-1 F TSC2 exon 36 4684G>A G1556S 12 m MM MR (–)?  + – –  +    –    
 III-3 F TSC2 exon 36 4684G>A G1556S  m MM MR (–)  –  –  +   +     
 III-2 F TSC2 exon 36 4684G>A G1556S  f MM MR (–)    –  +    +    
Verhoef (1998)
 Family A S TSC2 exon 36 4882 delTT 1628X 14 m FS MR (–)  ±  +  + + + – – –  – Dental pits
 Family B F TSC2 exon 36 4882 delTT 1628X 18 f FS MR (–)  +  +  + + + + + –  + 
 Family B mother F TSC2 exon 36 4882 delTT 1628X 40 f FS MR (–)  +  +  + + + + + –  + 
Niida (1999)
 185 S TSC2 exon 37 4858C>T H1620Y   MM MR  + Brain    + + – + –  – NA 
             image (+)
Au (1998)
 TS94–53  TSC2 exon 37 4859A>T N1620I   MM MR Beh/ + + NA  + + – – –  ± – Eye (–)
           LD (+)
Maheshwar (1997)
 n = 4,  unrelated S TSC2 exon 38 5042C>T P1675L   MM MR (–) 1,   3        1/1
          moderate MR 1,         exam-
          severe MR 2          ined
Niida (1999)
 277 S TSC2 exon 38 5024C>T P1675L   MM MR  + Brain   + – – – +  – + Retinal HM
             image (+)
Zhang (1999)
 28 S TSC2 exon 38 5042C>T P1675L 3 f MM MR  +  +  + NA
Feng (2004)
   7 F TSC2 exon 38 5042C>T P1675L 15 f MM Severe MR 
Hung (2006)
   4 S TSC2 exon 40 5227C>T R1743W  m MM MR (–)  + +   + + – + (+)?    
 50 S TSC2 exon 40 5227C>T R1743W  m MM MR  + +   + + – + NA    
Choi (2006)
 12 S TSC2 exon 40 5227–5244 del R1743–  m IF   + Tuber/    +      + + Retinal HM
      K1748 del       SEN (–) 
 13 S TSC2 exon 40 5227–5244 del R1743–  m IF   + Tuber/    +       + 
      K1748 del       SEN (+)
Martin (2003)
 Twin M F TSC2 exon 40 5256–73 del 1740– 6 m IF Severe MR  IS  +  + +   +  +  
      1745 del
 Twin T F TSC2 exon 40 5256–73 del 1740– 6 m IF Severe MR  Partial Sz + +  + +  + +   + 
      1745 del
Table 5.  TSC patients with identical mutations in the literature [vi]
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Rok (2005)
 Patient A S TSC2 exon 40 5238–5255 del del 1746  10 f IF MR(+)  Partial Sz + +  + + – – +  – + 
      HIKRLR
 Patient B S TSC2 exon 40 5238–5255 del del 1746  9 m IF MR(+)  IS + +  + + – – +  – – Retinal HM
      HIKRLR
 Patient C S TSC2 exon 40 5238–5255 del del 1746  9 f IF MR(–)  IS + +  + + – + +  – + 
      HIKRLR
 Patient D S TSC2 exon 40 5238–5255 del del 1746  1.5 ? IF MR(–)  IS + +  + – – – –  – + 
      HIKRLR
Dabora (2001)
 n = 9  TSC2 exon 40 5238–5255 del del 1746  7  IF MR none–   All (+)     None–    None– 
      HIKRLR –   severe       severe   exten-
       28             sive
Niida (1999)
 113 S TSC2 exon 40 5328–5255 del H1746Q/   MM/ MR (–)  – NA   + + + – +  – –
      1747–52 del   IF
Hung (2006)
 10 S TSC2 exon 40 5238–5255 del   f  LD  + +   + + – – –
 25 S TSC2 exon 40 5238–5255 del   m  LD  + +   + + – + –
Beauchamp (1998)
 S18-01 S TSC2 exon 40 5328–5255 del H1746Q/ 9  MM/ Mild MR  + Brain find-   + + + + +   +
      1747–52 del   IF    ings (+) 
The present study 
 Patient 8 S TSC2 exon 40 5238–5255 del del 1746 3 m IF Moderate– – IS + +  + +   –   +
      HIKRLR    severe MR
 Patient 9 S TSC2 exon 40 5238–5255 del del 1746 6 f IF Severe + IS,  + +  + –   –
      HIKRLR    MR  partial Sz
 Patient 10 S TSC2 exon 40 5238–5255 del del 1746 13 m IF Moderate  Partial IS + +  + –   –  +
      HIKRLR    MR
Lyczkowski (2007)
 B-II-1 (twin) F TSC2	 IVS1,  1838 bp del  6 f del IQ	85  Occasional 65 +  + +   +  + +
    exon 1 
 B-II-2 (twin) F TSC2 IVS1,  1838 bp del  6 f del IQ < 42  IS 60 +   +  + +  + +
    exon 1 
–, absent; +, present; ab, abnormality; AF, angiofibroma; AML, angiomyolipoma; Beh, behavioral problems; CI, cognitive impairment; CR, cardiac rhabdomyoma; DQ, developmental quotient; f, 
female; F, familial; FS, frameshift; HM, hamartoma; HPM, hypopigmented macule; IF, in-frame deletion; IS, infantile spasms; IVS, intervening sequence within an intron;	LD, learning disability; 
LGS, Lennox-Gastaut syndrome; m, male; MM, missense mutation; MR, mental retardation; NA, not available; NM, nonsense mutation; PUF, periungual fibroma; RCC, renal cell carcinoma; S, 
sporadic; SEGA, subependymal giant cell astrocytoma; SEN, subependymal nodule; s/o, suspect of; ShgP, Shagreen patch; SP, splice mutation; Sz, seizure; TSC, tuberous sclerosis complex; Var, 
variable; WML, white matter lesion.
Table 5.  TSC patients with identical mutations in the literature [vii]
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Discussion
 
Previous studies report that either TSC1 or TSC2 
mutations are found in 70% to 80% of TSC pa-
tients (Hung et al., 2006; Au et al., 2007).  The 
relatively low proportion of positive results in our 
series may have resulted from a selection bias that 
doctors in charge of patients with ambiguous clini-
cal phenotype tend to ask the genetic analysis to 
confirm the diagnosis.  However, mutations could 
be detected even in individuals with partial expres-
sion of TSC phenotype, for example, Patient 5 who 
did not show any cutaneous symptoms. 
 Some factors have been elucidated that could 
explain the variability of clinical manifestations 
in TSC patients, particularly neurological symp-
toms.  These include the mutated gene (TSC1 ver-
sus TSC2) (Dabora et al., 2001; Lewis et al., 2004; 
Sancak et al., 2005; Au et al., 2007), somatic 
mosaicism, history of infantile spasms (Lewis et 
al., 2004), and the number and volume of cortical 
tubers (Jansen et al., 2008).  Higher prevalence of 
severe intellectual disability in TSC patients with 
TSC2 mutations rather than TSC1 mutations may 
be related to the fact the tuberin plays a critical 
role in the phosphorylation of mTOR through its 
GAP activity and hamartin binds to tuberin and 
stabilizes the latter (Chong-Kopera et al., 2006). 
Somatic mosaicism in parents can explain the 
emergence of more severe phenotypes in their 
children (Rose et al., 1999).  Certain aspects of 
the data in our series of patients with identical 
mutations may be related to these mechanisms. 
However, somatic mosaicism cannot explain the 
mild phenotype of Patient 2, who was born to an 
affected TSC mother.  In addition, the basis for the 
differential manifestation of epilepsy and cortical 
tuber load between siblings, monozygotic twins, 
and members within a single family, remains 
unclear.  As for the two-hit theory, the second 
hit as somatic mutations have been detected in 
angiomyolipoma and giant cell astrocytoma of 
TSC patients, but not in ungual fibroma, pulmo-
nary lymphangiomyolipomatosis, and cortical 
tubers (Niida et al., 2001; Mizuguchi et al., 2004). 
Pathogenic significance of haploinsufficiency in 
tumor-suppressive genes has been also assumed in 
neurofibromatosis 1 (Easton et al., 1993; Henske et 
al., 1996), where marked intrafamilial variation is 
prevalent similarly to TSC.  Apparently there are 
other factors that modulate the phenotype of indi-
vidual TSC genotypes.  These may include somat-
ic mutation in other factors within the mTOR and 
other signaling pathways, and genetic background 
related to the epileptogenesis, or activation of the 
inflammatory system (Boer et al., 2008).  In addi-
tion, the significance and pathogenesis of mTOR 
pathway in the synaptic plasticity (Kelleher et al., 
2004), and decreased volume of subcortical gray 
matter (Ridler et al., 2007) in TSC patients need to 
be further explored to understand the variability of 
neurological manifestations.
 Most of the TSC1 mutations, and 2/3 of 
TSC2 mutations, causes truncation of the gene 
product proteins (Au et al., 2007).  The data in 
the identical mutation list (Table 5) correlate with 
this overall tendency.  As shown in this list, most 
of the mutations of TSC1/TSC2 genes in patients 
with mild intellectual disability are missense mu-
tations.  Relatively preserved tuberin-hamartin 
complex function may explain the mild phenotype 
in certain cases with missense mutations (Jansen 
et al., 2006).  In addition, given that the propor-
tion of missense mutations is relatively high in 
the GAP domain (Au et al., 2007), which has an 
essential role in the tuberin function, this type of 
mutations outside the GAP domain might remain 
subclinical and regarded as polymorphism.  On 
the other hand, various truncating mutations of 
TSC2 gene, whose GAP domain either preserved 
or untranslated, can result in both mild and severe 
intellectual and behavioral disabilities.  This again 
supports that other factors than the truncated gene 
product itself play critical roles in the determina-
tion of neurological phenotype. 
 Accumulation of mutation data with detailed 
clinical information is mandatory for a better un-
derstanding of genotype-phenotype correlation 
and the exploration of background mechanism. 
However, the mutation database and individual 
journal articles are often insufficient for collecting 
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clinical data and draw reliable conclusion.  Due 
to the aforementioned modifying factors of TSC 
phenotypes, interpretation of mutation data in indi-
vidual patient is most confusing.  We hope that the 
review data in this article would help the assess-
ment of mutations and provide research interest by 
doctors and investigators.
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